GILDGilead SciencesRunning, no new patients
Study of Novel Treatment Combinations in Patients With Lung Cancer
Lung Cancer · Advanced or Metastatic Non-Small-Cell Lung Cancer · Resectable Non-Small-Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 192 (final count)
- Started
- Mar 16, 2023
- Main results expected
- Sep 2029
- Fully finished
- Sep 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Substudies 01 and 02: Objective Response Rate (ORR) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Measured over: Up to 5 years
Substudy 03: Complete Pathological Response (pCR) Rate
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05633667 · record last updated 2026-06-01 · checked 2026-11-09 15:47 UTC